Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Provectus Pharmaceuticals (PVCT).
Provectus Biopharmaceuticals, Inc. has taken a significant step in leadership renewal by appointing Ed Pershing as its CEO and Dominic Rodrigues as President, both effective April 16, 2024. Pershing, who also serves as Chairman, brings extensive healthcare expertise from his time at PYA, a leading healthcare consulting firm he co-founded. Rodrigues, continuing as Vice Chairman, has a diverse background in management consulting, academia, and venture capitalism. Their combined experience is poised to steer Provectus towards new horizons in the biopharmaceutical industry. Both executives have entered into employment agreements with the company, with annual salaries of $240,000 and provisions for confidentiality, non-competition, and severance in the event of a change in control.
See more data about PVCT stock on TipRanks’ Stock Analysis page.